poisar

Stocks · News reference

Quanterix Lowers FY2026 Sales Guidance from $169.000M-$174.000M to $142.000M-$148.000M vs $169.930M Est

Aug 10, 2026, 12:00 PMBenzinga Newsdesk

Quanterix (NASDAQ:QTRX) lowers FY2026 sales outlook from $169.000 million-$174.000 million to $142.000 million-$148.000 million vs $169.930 million estimate.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

QTRX
Source
benzinga
Observed
Aug 10, 2026, 12:00 PM
Checked
Aug 10, 2026, 12:00 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 5:00 PMDelveinsight

    Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

    The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

    Read original at globenewswire-inc
    RHHBYABTTMODGXLH